



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/543,081

07/22/2005

Ole Simonsen

10200.204-US

1176

25908 7590 09/16/2010  
NOVOZYMES NORTH AMERICA, INC.  
500 FIFTH AVENUE  
SUITE 1600  
NEW YORK, NY 10110

EXAMINER

DOUYON, LORNA M

ART UNIT

PAPER NUMBER

1796

NOTIFICATION DATE

DELIVERY MODE

09/16/2010

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Patents-US-NY@novozymes.com

<b>Office Action Summary</b>	<b>Application No.</b> 10/543,081	<b>Applicant(s)</b> SIMONSEN ET AL.	
	<b>Examiner</b> Lorna M. Douyon	<b>Art Unit</b> 1796	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 09 June 2010.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 18-24, 26 and 29-35 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 18-24, 26 and 29-35 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)         | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)         | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                          |

***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 9, 2010 has been entered.
2. Claims 18-24, 26, 29-35 are pending. Claims 1-17, 25, 27-28, 36-40 are cancelled. Claims 18, 30 and 32 are currently amended.
3. The rejection of claims 36-39 under 35 U.S.C. 112, first paragraph is rendered moot in view of Applicants' cancellation of these claims.
4. The rejection of claims 18-24, 26-27, 29-40 under 35 U.S.C. 103(a) as being unpatentable over Green et al. (US 4,009,076) is withdrawn in view of Applicants' amendment.
5. The rejection of claim 28 under 35 U.S.C. 103(a) as being unpatentable over Green as applied to the above claims, and further in view of Rahman et al. (US Patent No. 6,355,607) is withdrawn in view of Applicants' amendment.

6. The rejection of claims 18-24, 26, 29-39 under 35 U.S.C. 103(a) as being unpatentable over Izawa et al. (US Patent No. 5,858,952) in view of Bertacchi et al. (US Patent No. 6,242,407) is withdrawn in view of Applicants' amendment.

7. The rejection of claims 27-28 and 40 under 35 U.S.C. 103(a) as being unpatentable over Izawa in view of Bertacchi as applied to the above claims, and further in view of Rahman is withdrawn in view of Applicants' amendment.

***Claim Rejections - 35 USC § 112***

8. Claims 18-24, 26, 29-31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. In independent claims 18 and 30, lines 2-3 of each, the phrase "core comprises/comprising ...20% w/w or more of acidic buffer component" is not supported in the specification and is considered as new matter. The specification on page 3, lines 20-21 states that "...more than 20% w/w of the total amount of acidic buffer component present in the granules is present in the core..." However, this does not provide basis for the limitation "the core comprises...20% w/w or more of acidic buffer component." The specification on page 5, lines 28-33 and page 6, lines 18-26, recite the amount of the acidic buffer component in the core, namely: at least 10% w/w; at least 25% w/w, at least 40% w/w, more than 50% w/w .... but no

mention of "20% w/w or more". Hence, the added limitations in the claims lack literal basis in the specification as originally filed, see *Ex parte Grasselli*, 231 USPQ 393 (Bd. App. 1983) affd mem. 738 F.2d 453 (Fed. Cir. 1984).

### ***Claim Rejections - 35 USC § 103***

9. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

10. Claims 18-24, 26, 29-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Green et al. (US 4,009,076), hereinafter "Green" in view of Mimura et al. (WO 01/40428), hereinafter "Mimura".

Green teaches enzyme granules, particularly for detergent compositions, comprising a granule core of solid material carrying an enzyme and a solid coating of plasticized resin free of the enzyme (see abstract). The carrier material of the core will be of solid non-friable substance suitable for carrying the enzyme, for instance a water-soluble substance which can have detergent or detergency builder properties, especially a detergency builder salt, and examples are sodium tripolyphosphate, sodium carbonate and sodium hexametaphosphate (see col. 2, lines 47-63). The enzyme carried on the granular core material can be an oxidoreductase, transferase, isomerase or hydrolase (see col. 3, lines 1-3). The solid material carrying the enzyme can be agglomerated with a cohesive organic material to form a core, and when present, it will usually provide from 2 to 50% by weight of the granule core, and the amount of enzyme

Art Unit: 1796

will be chosen according to the activity of the enzyme concentrate available (see col. 3, lines 46-53), the remainder of the granule core will be the amount of the carrier. In Example 1, the carrier (which is granular sodium tripolyphosphate) is present in an amount of about 89% of the granule core ( $81/91.1 \times 100 = 89\%$ ), see col. 5, lines 60-67.

The preparation of the granule core can be carried out by conventional methods, for example, an enzyme powder can be mixed with the carrier and a concentrated solution of organic material sprayed on to it and the resulting mass extruded and formed into noodles (see col. 3, line 66 to col. 4, line 5), and thereafter coating the granule core in a Lodige mixer, a pan coater or a drum granulator (see col. 4, lines 6-43). Green also teaches a solid detergent composition comprising enzyme granules as described above (see col. 4, lines 44-47). In Example 8 and 9, Green teaches granule cores which are given a preliminary coating by atomizing on to them in the Lodige mixer a 6.1% solution of anhydrous citric acid (which reads on the acidic buffer coating in claim 21) in the same ethylene oxide condensate as was present in the slurry (the solution containing 20% citric acid), and the resulting granule cores were further coated with dextrin and glucose (see col. 6, line 49 to col. 7, line 14). It is seen in these examples that the amount of the carrier ( i.e., sodium tripolyphosphate) in the core is more than 20% of the total amount of the acid (i.e, sodium tripolyphosphate + citric acid) in the granule (as required in claim 22). Green, however, fails to specifically disclose the carrier to be sodium dihydrogen phosphate, potassium dihydrogen phosphate or disodium monohydrogen citrate in amounts as those recited; the pH and  $pK_a$  values of the acidic buffer component.

Mimura, an analogous art, teaches the equivalency of sodium tripolyphosphate or sodium carbonate with sodium dihydrogen phosphate, potassium dihydrogen phosphate or disodium monohydrogen citrate as buffering agents or builders (see page 15, lines 13-20).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have substituted the sodium tripolyphosphate of Green with sodium dihydrogen phosphate, potassium dihydrogen phosphate or disodium monohydrogen citrate because the substitution of art recognized equivalents as shown by Mimura is within the level of ordinary skill in the art. In addition, the substitution of one builder for another is likely to be obvious when it does no more than yield predictable results.

With respect to the proportions of the carrier material, it would have been obvious to one of ordinary skill in the art at the time the invention was made to optimize the proportions of the carrier material because it has been held to be obvious to select a value in a known range by optimization for the best results. As to optimization results, a patent will not be granted based upon the optimization of result effective variables when the optimization is obtained through routine experimentation unless there is a showing of unexpected results which properly rebuts the prima facie case of obviousness. See *In re Boesch*, 627 F.2d 272,276,205 USPQ 215,219 (CCPA 1980). See also *In re Woodruff*, 919 F.2d 1575, 1578,16 USPQ2d 1934, 1936-37 (Fed. Cir. 1990), and *In re Aller*, 220 F.2d 454,456,105 USPQ 233,235 (CCPA 1955). In addition, a *prima facie* case of obviousness exists because the claimed ranges "overlap or lie inside ranges

Art Unit: 1796

disclosed by the prior art", see *In re Wertheim*, 541 F.2d 257,191 USPQ 90 (CCPA 1976; *In re Woodruff*; 919 F.2d 1575,16USPQ2d 1934 (Fed. Cir. 1990). See MFEP 2131.03 and MPEP 2144.05I.

With respect to the pH and pK<sub>a</sub> values of the carrier material, it would have been obvious to one of ordinary skill in the art at the time the invention was made to reasonably expect the pH and pK<sub>a</sub> values of the carrier material (i.e., acidic buffer components) to be within those recited because similar components have been utilized.

### ***Response to Arguments***

11. Applicant's arguments with respect to claims 18-24, 26, 29-35 have been considered but are moot in view of the new ground(s) of rejection.

### **Conclusion**

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lorna M. Douyon whose telephone number is 571-272-1313. The examiner can normally be reached on Mondays-Fridays 8:00AM-4:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Harold Pyon can be reached on 571-272-1498. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Art Unit: 1796

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Lorna M Douyon/  
Primary Examiner, Art Unit 1796